+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.

Age: 18Years +All GendersPhase 2
40 locations
I

Actively Recruiting

This research aims to improve treatment for children and adolescents newly diagnosed with lymphoblastic lymphoma. The trial is a large, international, randomized clinical study involving multiple countries and specialized centers. It focuses on whether using dexamethasone instead of prednisone during the induction phase can reduce relapses in the central nervous system CNS, and for high-risk patients, whether an intensified treatment improves event-free survival compared to standard therapy. Participants are grouped by risk level based on disease characteristics like CNS involvement and genetic markers. All patients first receive a prednisone prephase, then are randomized to either standard induction with prednisone or experimental induction with dexamethasone. Treatment phases include consolidation, extra-compartment phases adjusted by risk group, reintensification for some groups, and maintenance therapy lasting up to 24 months. Patients with CNS involvement receive intensified intrathecal therapy without cranial irradiation. High-risk patients may undergo a second randomization to receive either standard or intensified treatment during later phases. During the study, patients undergo various treatments including chemotherapy drugs such as cyclophosphamide, methotrexate, and PEG asparaginase. Researchers monitor disease relapse involving the CNS and measure event-free survival over a maximum of 7.25 years. Secondary assessments include overall survival, treatment-related toxicity and mortality, adverse events, and molecular markers. The trial involves ongoing follow-up for safety and effectiveness outcomes throughout the study period, which can last several years.

Age: 0 - 18YearsAll GendersPhase 3
228 locations
P

Actively Recruiting

Researchers are studying patients with newly diagnosed H3 K27M-mutant diffuse glioma to see if the drug dordaviprone ONC201 after standard radiotherapy can help extend overall survival and delay disease progression. This international Phase 3 trial is randomized, double-blind, and placebo-controlled to carefully evaluate treatment effects in this specific patient group. Participants must have a confirmed diagnosis of this glioma subtype and have completed frontline radiotherapy. Participants are randomly assigned to one of three groups dordaviprone taken twice weekly, dordaviprone taken once weekly, or a matching placebo. Dosing is adjusted based on body weight, with a standard dose of 625 mg for patients weighing 52.5 kg or more. The study treatment starts after completion of radiotherapy and continues under close monitoring. Throughout the study, participants undergo regular assessments including brain MRIs, laboratory tests, and evaluations of neurological function and quality of life. Researchers will monitor overall survival over approximately 44 months, as well as progression-free survival, corticosteroid use, performance status, and symptom changes. Safety and lab parameters will be tracked closely to understand treatment effects and participant well-being during the trial period.

All AgesAll GendersPhase 3
162 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness and safety of combining pembrolizumab with lenvatinib in women with vulvar squamous cell carcinoma VSCC that is recurrent, persistent, metastatic, or locally advanced and cannot be treated with surgery or radiation. This phase II, open-label, single-arm study focuses on patients who have limited treatment options due to the advanced nature of their cancer. Participants receive pembrolizumab 400 mg every six weeks along with daily doses of lenvatinib at 20 mg. The study monitors these treatments over time to assess their combined impact on the disease. This trial does not include a comparison group and follows patients through treatment to observe outcomes. During the study, patients undergo regular evaluations including scans to measure tumor response, lab tests, and assessments of quality of life. Researchers track the overall response rate within 24 weeks as the primary outcome and also evaluate disease control, duration of response, survival rates, and safety throughout treatment and up to 40 months. Adverse events and patient-reported outcomes are closely monitored to understand treatment effects and tolerability.

Age: 18Years +FEMALEPhase 2
15 locations
C

Actively Recruiting

Researchers are studying treatments for adults with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors overexpress HER2 and have PD-L1 TPS less than 50%. This trial compares the combination of trastuzumab deruxtecan T-DXd with pembrolizumab against platinum-based chemotherapy combined with pembrolizumab. Participants have not received prior therapy for their advanced or metastatic NSCLC and lack known actionable genomic alterations with available targeted treatments. The study involves two treatment groups. One group receives T-DXd at 5.4 mgkg intravenously every three weeks alongside pembrolizumab at 200 mg IV every three weeks. The other group receives pemetrexed at 500 mgm IV every three weeks plus a platinum chemotherapy agent cisplatin or carboplatin combined with pembrolizumab at 200 mg IV every three weeks. Treatment continues as per protocol for first-line therapy in this population. Participants will be monitored regularly for disease progression and survival outcomes, with progression-free survival assessed by independent central review up to approximately 54 months and overall survival up to about 85 months. Tumor tissue samples will be assessed for HER2 and PD-L1 expression. Safety and treatment effects will be evaluated throughout the study, which may last several years until study completion in 2032.

Age: 18Years +All GendersPhase 3
246 locations